DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Jørgensen KK, Olsen IC, Goll GL. et al
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Lancet 2017;
389: 2304-2316 . doi:10.1016/S0140-6736(17)30068-5
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.